Duchenne News Tags: Sarepta Therapeutics

Sarepta shares an update on efficacy supplement for ELEVIDYS.

Sarepta shares topline results from the EMBARK study and more in a Community Letter.

Sarepta announces U.S. Food and Drug Administration accelerated approval of ELEVIDYS.

Sarepta shares enrollment updates for SRP-9001-303 study.

Sarepta shares an update on the regulatory review of SRP-9001, a treatment of ambulant individuals with Duchenne muscular dystrophy who have a confirmed mutation of the DMD gene.

Sarepta Therapeutics Announces May 12, 2023 as Date of Advisory Committee Meeting for SRP-9001

Sarepta announces advisory meeting for SRP-9001, an investigational gene therapy for the treatment of Duchenne muscular dystrophy.

Sarepta announces official release of 2023-2024 Route 79 Duchenne Scholarship Program

Sarepta announces FDA filing and priority review for biologics license application for SRP-9001

Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy.

On September 13, 2022, Sarepta Therapeutics shared an update announcing that their EMBARK (SRP-9001-301) study is fully enrolled.

On Sept. 7, 2022, Sarepta Therapeutics announced the recipients for its Route 79, Duchenne Scholarship Program for the 2022-2023 academic year.

On Sept. 6, 2022, Sarepta Therapeutics announced that the Food and Drug Administration lifted its clinical hold on SRP-5051 for the treatment of Duchenne muscular dystrophy.